Buy Retatrutide 20 mg Pen in the UK
A triple GLP-1 / GIP / glucagon agonist in a pre-filled 3 mL click pen. The 20 mg pen for metabolic research. Each click delivers 67 µg from a 3 mL · 300-click pen.
Featured in these stacks: Summer Stack.
how many clicks
for your dose?
This Retatrutide 20 pen holds 20 mg across 300 clicks, so each click delivers 67 µg. Tap a dose or turn the dial; we'll count the clicks. For research reference only.
why researchers chose this pen
chose it for the click dosing, no syringes, no unit maths.
verified purity, checked against the public CoA before first use.
precise clicks in every 3 mL pen, the whole protocol in one barrel.
re-order or refer a colleague within three months.
about the
Retatrutide 20 pen
Retatrutide is an investigational triple incretin receptor agonist, supplied in a pre-filled 3 mL / 300-click pen for in-vitro research. Each batch is independently assayed.
Certificate of analysiswhy a pen beats
a vial & syringe
Traditional research peptides arrive as lyophilised powder that must be reconstituted, drawn into insulin syringes, and converted from milligrams to units by hand, every step a chance for a dosing error.
A multi-dose pen removes the whole failure chain. The peptide arrives already dissolved and calibrated. Attach a fresh needle, turn the dial until you count your clicks, and you're done, the same audible-click mechanism trusted in insulin and GLP-1 pens worldwide.
Pens travel and store better, too: no open vials, no bent needles, no septum contamination after repeated draws. One sealed barrel, ten sterile needles, one dosing card.
how to buy
peptides safely
The peptide market has a purity problem: independent surveys routinely find underdosed, mislabelled or contaminated product sold online. The only reliable defence is third-party verification you can check yourself, not a supplier's own claims.
Before buying any peptide pen, ask three questions. Is every batch tested by an independent lab? Is the certificate of analysis available, so you can check your exact lot before first use? And does it ship cold-chain, insulated and gel-packed, so what was tested is what arrives?
Veyvora answers yes on every order, independent assay, a CoA on request against the batch number, and cold dispatch within 24 hours, paperwork packed inside.
pairs well with
view all
Overview
Veyvora’s Retatrutide 20 mg Pen is a pre-filled 3 mL, 300-click research-format pen containing LY3437943, an investigational triple receptor agonist of glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon pathways, supplied for in-vitro laboratory research. At 20 mg across 300 clicks, each click delivers approximately 67 µg. Retatrutide is an investigational compound in clinical development, so the research pen is its laboratory presentation; the compound’s receptor pharmacology and trial literature are covered in the linked research pages.
| Specification | Detail |
|---|---|
| Active compound | Retatrutide (LY3437943) |
| Total content | 20 mg |
| Fill volume | 3 mL |
| Click count | 300 |
| Dose per click | ≈ 67 µg |
| Intended use | In-vitro laboratory research only |
Price: Current pricing is a live figure on the Veyvora product page and is not reproduced here.
Availability and purchase path: The research-procurement route is to request the batch-specific certificate of analysis from Veyvora, verify it against the pen’s batch number, then order the pen for laboratory use.
Product Identity and Scope
Veyvora’s Retatrutide 20 mg Pen is a pre-filled 3 mL, 300-click research-format pen containing LY3437943, an investigational triple receptor agonist of GLP-1, GIP, and glucagon pathways, supplied for in-vitro laboratory research. Each click delivers approximately 67 µg from the 20 mg total. The triple-agonist mechanism, acting at three receptors involved in glucose regulation and energy balance, is what distinguishes retatrutide from the single- and dual-receptor agonists in the same class.
| Specification | Detail |
|---|---|
| Active compound | Retatrutide (LY3437943) |
| Total content | 20 mg |
| Fill volume | 3 mL |
| Click count | 300 |
| Dose per click | ≈ 67 µg |
| Intended use | In-vitro laboratory research only |
Before first use, verify your batch against its certificate of analysis (CoA) to confirm the pen and batch number match the public certificate.
Verified Specifications
Veyvora’s Retatrutide 20 mg Pen is specified as a pre-filled 3 mL pen containing 20 mg of retatrutide (LY3437943) across 300 clicks, yielding approximately 67 µg per click. That figure comes from Veyvora’s product data; the batch certificate reports the measured content for the lot supplied, and the click-count and dose-per-click values below are Veyvora’s stated specification.
| Specification | Veyvora-stated value | Where it is reported |
|---|---|---|
| Active compound | Retatrutide (LY3437943) | Batch CoA (LC-MS identity) |
| Total content | 20 mg | Batch CoA |
| Fill volume | 3 mL | Batch CoA |
| Click count | 300 | Veyvora product data |
| Dose per click | ≈ 67 µg | Arithmetic from 20 mg ÷ 300 clicks |
| Needle compatibility | Confirm with operator | Veyvora product data |
| Intended use | In-vitro laboratory research only | Veyvora product data |
Phase 2 clinical work on retatrutide described weekly subcutaneous administration of the investigational compound (Jastreboff et al., NEJM, 2023); the click-to-mg mapping above is Veyvora’s own presentation of the 20 mg fill in the multi-dose pen format.
For storage conditions that apply to this format, see Retatrutide storage and stability guidance. For mechanism and published-evidence context, the Retatrutide research profile covers the compound’s receptor pharmacology; this page covers the pen’s specification.
Batch Documentation and Analytical Evidence
Each retatrutide pen ships with an independent, batch-specific certificate of analysis (CoA) reporting LC-MS identity, HPLC purity (≥ 98.0%), peptide content (95–105%) and a safety panel, so the material is characterised before any research use. Veyvora states that each batch is verified independently by Asterion Analytics, then again by Veyvora’s own internal testing, using high-performance liquid chromatography (HPLC), mass spectrometry, and endotoxin assay, with the CoA matched to the batch number before first use (Veyvora quality documentation, 2026). The CoA is the analytical record for the lot; match the batch number on the pen to the published certificate before use.
Before placing an order, confirm that the CoA on the live product page carries the exact batch number of the pen being dispatched, names the analytical method and laboratory, and states the result against a defined acceptance criterion.
Reading the Certificate of Analysis
The LC-MS line confirms identity by matching the measured mass to the expected mass of retatrutide. The HPLC line reports chromatographic purity for the tested aliquot against the ≥ 98.0% acceptance criterion, and the peptide content line reports the measured quantity against the stated fill, within 95–105%. The endotoxin result applies to the sample submitted, under the conditions of that test run. Confirm that the certificate is tied to the specific batch number on the pen and that it names the analytical method, laboratory and the acceptance criterion applied.
Receptor-Pharmacology Context
For compound-level context, the Retatrutide versus Tirzepatide comparison addresses the receptor-pharmacology differences between the triple and dual agonists.
Handling and Storage
Veyvora states that orders are dispatched cold in an insulated bag with a gel ice pack (Veyvora cold-chain specification, 2026). Peptide solutions are temperature-sensitive as a class, so the cold-chain packaging keeps the pen within its dispatch range in transit.
Storage Conditions
For the storage range after receipt, in-use shelf life, freeze-thaw limits and pen-in-use periods, use the live product label or structured data sheet for the specific batch being received, and ask Veyvora for any value not on them before first use. To match your pen’s storage conditions to its documented analytical results, verify your batch against its CoA before opening the packaging.
Ordering Information
GBP price, current stock level and delivery timescales are live values on the Veyvora product page and are not reproduced here; confirm them at the point of order.
Research Procurement Route
Veyvora supplies the retatrutide 20 mg pen for in-vitro laboratory research. To procure, request the batch-specific certificate of analysis, verify it against the pen’s batch number, then order the pen for laboratory use. For Veyvora’s documented cold-chain packaging and in-vitro supply terms, the Retatrutide storage and stability guidance covers the supplier’s stated 2–8 °C dispatch policy.
Research Use
The Veyvora Retatrutide 20 mg Pen is supplied for in-vitro laboratory research, such as receptor-binding and signalling assays, cell-culture work and use as an analytical reference material. Not for human or veterinary use. For a procurement audit trail, match each pen’s batch number to its published certificate of analysis and retain the certificate as the analytical record for that lot.
Researchers exploring related research pens can review Veyvora’s verified research-peptide catalogue for other in-vitro supply options.
Related Research and Comparison Pages
The efficacy and safety context for retatrutide (LY3437943) sits in the peer-reviewed trial literature. Jastreboff et al., published in the New England Journal of Medicine on 26 June 2023, is the Phase 2 obesity reference; ongoing Phase 3 work is registered under Lilly’s TRIUMPH programme on ClinicalTrials.gov, with records spanning 2024–2026 [1]. Confirm NCT numbers directly on the live register before citing them, as trial status changes.
Before placing any order, verify your batch against its CoA by matching the batch number on your retatrutide pen to the public certificate of analysis. Where the certificate lists an HPLC purity figure, what HPLC purity does and does not prove explains how it is measured: assay purity describes the tested aliquot, identity is confirmed by the LC-MS line, and endotoxin by its own assay.
Sources
[1] Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial, New England Journal of Medicine, 2023, https://doi.org/10.1056/NEJMoa2301972
